Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. TECX
TECX logo

TECX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Tectonic Therapeutic Inc (TECX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Buy
Latest Price
31.990
1 Day change
3.09%
52 Week Range
36.030
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Tectonic Therapeutic Inc (TECX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong analyst support with significant upside potential, hedge fund buying trends, and bullish technical indicators, making it a compelling opportunity despite the lack of recent news or financial data.

Technical Analysis

The MACD is positive and expanding (0.119), indicating bullish momentum. The RSI (58.764) is neutral but leaning towards bullish territory. Moving averages are bullish with SMA_5 > SMA_20 > SMA_200. The stock is trading near its pivot level of 29.264, with resistance at 30.811 and 31.767, and support at 27.717 and 26.761.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
4
Buy
10

Positive Catalysts

  • Analysts have upgraded TECX to Strong Buy with a price target of $81, citing two potential blockbuster clinical-stage assets.

  • Hedge funds are significantly increasing their positions (+215.50%).

  • Bullish technical indicators and favorable stock trend analysis for the next month (+1.34%).

Neutral/Negative Catalysts

  • No recent news or event-driven catalysts.

  • Lack of financial performance data for the latest quarter.

  • Neutral insider trading activity.

Financial Performance

No financial data available for the latest quarter.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Raymond James upgraded TECX to Strong Buy with an $81 price target, citing an attractive valuation and promising clinical-stage pipeline assets. Stifel initiated coverage with a Buy rating and a $75 price target, highlighting compelling risk/reward ahead of Phase 2 APEX data expected in late 2026 to early 2027.

Wall Street analysts forecast TECX stock price to rise
7 Analyst Rating
Wall Street analysts forecast TECX stock price to rise
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 31.030
sliders
Low
60
Averages
81
High
101
Current: 31.030
sliders
Low
60
Averages
81
High
101
Raymond James
Martin Auster
Outperform -> Strong Buy
upgrade
$76 -> $81
AI Analysis
2026-05-26
Reason
Raymond James
Martin Auster
Price Target
$76 -> $81
AI Analysis
2026-05-26
upgrade
Outperform -> Strong Buy
Reason
Raymond James analyst Martin Auster upgraded Tectonic Therapeutic to Strong Buy from Outperform with a price target of $81, up from $76. The company offers an \"uncommonly attractive opportunity,\" trading at an enterprise value of $300M with two potential blockbuster clinical-stage pipeline assets, the analyst tells investors in a research note. The firm says that while TX45 and TX2100 \"will need incremental de-risking for investors to realize a major upside valuation reset,\" both programs are built on \"solid\" biological rationale and address areas of major unmet need.
Stifel
Buy
initiated
$75
2026-04-13
Reason
Stifel
Price Target
$75
2026-04-13
initiated
Buy
Reason
Stifel initiated coverage of Tectonic Therapeutic with a Buy rating and $75 price target. The firm thinks the risk/reward ahead of the Phase 2 APEX data due in late 2026 to early 2027 is \"compelling\" and remains \"cautiously optimistic\" that Tectonic has a fundamentally better drug and trial than in prior relaxin failures, the analyst tells investors.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for TECX
Unlock Now

People Also Watch